Skip to main content

BioAdaptives Completes MyndSystem™ Platform with TruShield Certification of MyndRenew™, Securing Full WADA Compliance for Professional Athletes and Expanding Market Opportunity

Written by Customer Service on . Posted in Public Companies.

Certification validates the complete day-and-night neuro-performance and repair system, positioning the company for broader adoption across elite sports and high-value consumer segments

LAS VEGAS, June 25, 2026 (GLOBE NEWSWIRE) — via IBN – BioAdaptives, Inc. (OTC: BDPT), the parent company of MyndSystem™, today announced that its nighttime repair formula, MyndRenew™, has received TruShield Certified status. This independent verification confirms that MyndRenew meets the rigorous anti-doping standards of the World Anti-Doping Agency (WADA) and the Ultimate Fighting Championship (UFC). Combined with the prior TruShield certification of MyndMed™ (the daytime performance formula), the full MyndSystem™ duo is now officially cleared for use by professional fighters and athletes subject to strict anti-doping protocols.

With this certification, MyndRenew™ joins MyndMed™ — which received TruShield™ clearance in August 2025 — to form the first complete, fully WADA-compliant 24/7 cognitive performance and repair system for professional athletes.

MyndSystem™ was originally developed for UFC fighters. The platform has since shown strong results across three key demographics that face similar challenges of accelerated brain stress and cognitive wear: professional fighters in their 20s, high-performing executives in their late 30s and 40s, and active seniors aged 55 and older. This broad applicability underscores the platform’s science-backed approach to daytime cognitive performance (MyndMed™) and overnight brain repair and recovery (MyndRenew™).

“Securing TruShield certification for the complete MyndSystem is a major milestone,” said Jamers Keener, CEO of BioAdaptives. “It not only validates the safety and quality of our formulations for the world’s most scrutinized athletes but also significantly strengthens our position in the rapidly growing sports nutrition and performance supplement markets. With both products now WADA-compliant, we are well-positioned to pursue partnerships and adoption opportunities across professional leagues, including the UFC, and potentially other major sports organizations that prioritize clean, effective supplementation.”

Strategic Implications for Shareholders

This certification enhances BioAdaptives’ credibility and competitive differentiation within the premium performance nutrition category. Key potential benefits include:

For BioAdaptives shareholders, the certification marks an important commercial-readiness milestone. The Company believes that independent banned-substance certification may reduce a key barrier to adoption among professional and tested athletes, strengthen the credibility of the MyndSystem™ platform, and support future marketing initiatives for three primary audiences:

The Cage: combat athletes, mixed martial arts fighters, trainers, and high-intensity competitors.

The Boardroom: executives, entrepreneurs, and professionals operating under sustained cognitive demand.

The Journey: active aging adults seeking to maintain mental clarity, resilience, sleep quality, and daily performance.

The key potential benefits of the MyndSystem™ include:

  • Access to Elite Athlete Markets — Official clearance opens pathways to inclusion in UFC-approved supplement pools and similar programs used by other professional leagues, such as the NFL, NBA, and NHL.
  • Broader Consumer Trust — Independent WADA-level verification builds confidence among athletes, coaches, teams, and performance-focused consumers across all three target demographics.
  • Market Expansion Opportunity — The platform’s proven relevance to fighters, executives, and seniors enables multiple high-value revenue streams across the sports nutrition, corporate wellness, and longevity markets.
  • Long-Term Brand and Shareholder Value — This milestone supports brand elevation, potential strategic partnerships, and sustainable growth as the company scales the commercialization of the MyndSystem™ platform.

BioAdaptives continues to focus on science-backed, natural formulations that support cognitive performance and recovery while upholding the highest standards of safety and compliance.

Availability

MyndSystem™, MyndMed™, and MyndRenew™ are now available at www.myndsystem.com. A 30-day supply of the complete MyndSystem™ is available as a one-time purchase for $159.90 or via subscription (cancel anytime) for $119.93. A 14-Day Discovery Pack of both is available for $59.95. All products include a 100-day money-back guarantee. Additional product information, full ingredient profiles, and supporting research are also available at the same address.

BioAdaptives, Inc. provides ongoing updates via X (formerly Twitter) at @BioAdaptivesInc.

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based health and wellness products for humans and animals. Its formulations are grounded in published research on nutrition, adaptogens, and cellular health, with a focus on supporting normal physiological function.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product positioning, intended benefits, market opportunity, and future business strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. BioAdaptives undertakes no obligation to update these statements except as required by law.

INVESTOR & MEDIA CONTACT

Emily Harrison
Investor Relations, BioAdaptives, Inc.
(702) 703-1233 | info@bioadaptives.com | www.bioadaptives.com
X – @BioAdaptivesInc

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.